Biomarkers in oncology drug development: rescuers or troublemakers?

Bibliography

• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Dev 2004;3:711-5
   PubMed Web of Science ®Google Scholar
• FDA website of validated genomic biomarkers. Available from: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm
   Google Scholar
• Gutman S. Office of In Vitro Diagnostic Device Evaluation and Safety, US Food and Drug Administration, Lichtenfeld L, American Cancer Society, FDA teleconference, 6 February 2007
   Google Scholar
• Wittner BS, Sgroi DC, Ryan PD, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008;14:2988-93
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:1-10
   PubMed Web of Science ®Google Scholar
• Ross JS, Hatzis C, Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008;13:477-93
   PubMed Web of Science ®Google Scholar
• Bueno-De-Mesquita JM, Van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007;8(12):1079-87
   PubMed Web of Science ®Google Scholar
• Haferlach T, Bacher U, Kern W, et al. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 2007;86(5):311-27
   PubMed Web of Science ®Google Scholar
• Bolufer P, Colomer D, Gomez MT, et al. Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: multiinstitutional laboratory trial. Clin Chem 2004;50(6):1088-92
   PubMed Web of Science ®Google Scholar
• Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004;91:1-30
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw 2008;2:S37-42.
   Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;15:2542-51
   Google Scholar
• Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;15:2594-6
   Google Scholar
• Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw 2008;6(Suppl 2):S31-6
   PubMedGoogle Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105(6):2070-5
   PubMed Web of Science ®Google Scholar
• Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13(10):2890-6
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104(52):20932-7
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Presentation at the 2008 ASCO Annual Meeting, 2008, Boston
   Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst 2005;97:339-46
   PubMed Web of Science ®Google Scholar
• Timar J, Lang I. The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer. Magy Onkol 2008;52(2):185-91
   PubMedGoogle Scholar
• Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006;12(23):7180-6
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park) 2008;22(4):430-7
   PubMed Web of Science ®Google Scholar
• Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005;23(25):6107-16
   PubMed Web of Science ®Google Scholar
• De Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006;10:135-51
   PubMed Web of Science ®Google Scholar
• Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21(11):2311-5
   PubMed Web of Science ®Google Scholar
• Dieterle F, Marrer E, Suzuki E, et al. Monitoring kidney safety in drug development: emerging technologies and their implications. Curr Opin Drug Discov Devel 2008;11(1):60-71
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, EMEA. Available from: www.emea.europa.eu/htms/human/mes/biomarkers.htm
   Google Scholar
• Dieterle F, Marrer E. New technologies around biomarkers and their interplay with drug development. Anal Bioanal Chem 2008;390(1):141-54
   PubMed Web of Science ®Google Scholar
• Woude GF, Kelloff GJ, Ruddon RW, et al. Reanalysis of cancer drugs: old drugs, new tricks. Clin Cancer Res 2004;10:3897-907
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45
   PubMed Web of Science ®Google Scholar
• Jonathan KC. Knowles discusses the impact of pharmacogenomics on market segmentation. Nat Rev Drug Discov 2004;3:822
   PubMed Web of Science ®Google Scholar
• Goulart BHL, Clark JW, Pien HH, et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007;13(22):6719-26
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise or expensive distraction? Clin Cancer Res 2007;13(22):6545-8
   PubMed Web of Science ®Google Scholar
• Workman P. Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 2008;14(8);2512
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. N Engl J Med 2008;359(4):366-77
   PubMed Web of Science ®Google Scholar
• Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52
   PubMed Web of Science ®Google Scholar
• Cossman J. Companionship on the Critical Path, Presentation at the Ventana Symposium, 2008; Paris
   Google Scholar